Pharming « Terug naar discussie overzicht

Nanoporous microneedle array technology

7 Posts

Omlaag ↓

pakman 18 december 2020 12:48

Microbiology Industry Survey

Novel microneedle array developed to deliver COVID-19 vaccine to mice
Researchers have created a microneedle array that successfully delivered a COVID-19 vaccine to mice, allowing them to produce antibodies against the virus.

www.europeanpharmaceuticalreview.com/...
- - -
www.knowmade.com/microneedle-patch-in...
- - -
mylife technologie/Pharming ...

mylifetechnologies.nl/vaccine-deliver...

[verwijderd] 6 januari 2021 12:45

mylife technologies site niet meer in de lucht...

www.biotechnews.eu/fileadmin/pdf/2020...

pag. 4
..
Het Leidse MyLife Technologies heeft een alternatief
ontwikkeld voor naaldinjecties, orale tabletten en
capsules om geneesmiddelen toe te dienen: een
pleister met poreuze micronaalden. De pleister
kan geneesmiddelen en vaccins pijnloos via de
huid toedienen en leent zich uitstekend voor
zelftoediening en dagelijkse doseringen. ‘Vooral in
het geval van vaccins- is toediening via de huid soms
zelfs te prefereren: op deze manier kunnen de vele
immuuncellen in de (opper)huid effectiever bereikt
worden dan de standaard injectie in spieren, met een
betere immuunreactie tot gevolg of 3x-10x minder
vaccinstoffen,

3 tot 10x minder nodig HALLO..... denk dat het gaat gebeuren ...begint met een O ;-)

[verwijderd] 6 januari 2021 12:53

zie het al gebeuren , aankondiging en dan op de US beurs..... Sijmen ,you can do it !!!

[verwijderd] 11 januari 2021 09:49

News

December 2020: MyLife Technologies is awarded the MIT R&D Development grant with partner 20Med from Enschede (NL). MyLife combines its intradermal microneedle arrays with 20Med's mRNA nanoparticles as a rapid-response technology for new outbreaks of infectious diseases. The proposal was ranked first place out of 20+ high tech propositions in the East Region of the Netherlands. The project may also be relevant for cancer therapies using mRNA- or DNA-vaccines as nano particles.

September 2020: MyLife is awarded the prestigious Eureka InnoWide grant with its market screening project to define development and entry of improved HPV-vaccines for Indian markets together with Indian Partner Transform SciTech. The proposal was ranked first place out of 700+ enteries.

July 2020: MyLife closes €0.9 Mln as first half of its intermediate round to establish the company as a Technology Platform provider for vaccine delivery. The company focuses on vaccine delivery in the skin to enhance the performance of modern vaccines, both for therapeutic and for prophylactic uses.
The proceeds are used to: 1) scale-up its micro-needle processing technology; and 2) demonstrate with partners vaccine delivery projects using its proprietary ceramic nano-porous Micro Needle Array technology.

June 2020: Outcome of the First-in HUman studies with healthy volunteers concludes the npMNA's with and without a commercially available pharmaceutical peptide drug loading to be safe and applicable as conducted by Center of Human Drug Research in July-August 2019

March 2020: Mylife Technologies is selected to enter the EIT Health 'Start-ups meet Pharma' project. The project combines companies with Pharma partners looking for specific technologies or opportunities.

January 2020: MyLife Technology appoints Mike de Leeuw as new CEO, with focus on the transition to offering its npMNA Technology Platform to especially vaccine developers in applications for cancer therapies and infectious diseases (coming from the previous single product development strategy).

[verwijderd] 11 januari 2021 09:58

Als ik Sijmen was wist ik wel in welk bedrijf Pharming , na Bioconnection, ook een belang zou nemen ....

[verwijderd] 23 januari 2021 12:36

www.upmc.com/coronavirus/pittcovacc

zij doen er ook al iets mee en zeggen ook toepasbaar voor Covid-19, zie het al voor me/gebeuren

Ruconest SOC for Covid-19 delivery through a microneedle array..Wereldnieuws.

pakman 17 november 2021 15:45

MyLife Technologies raises US$4.0 million to further develop its vaccine delivery technology through painless ceramic vaccine patches for 'Pandemic Preparedness'

Simple vaccine patch using a much lower vaccine dose than injection, preventing trypanophobia or needle anxiety
Easier to store vaccines, fewer side effects and lower costs
Contributes significantly to early containment of potential epidemics/pandemics in low- and middle-income countries
Lowers threshold for HPV vaccination against cervical cancer
Collaboration with international vaccine companies and global NGOs

Leiden, The Netherlands, 12 November 2021 – MyLife Technologies, a Dutch vaccine and drug delivery company, focusing on the development of ceramic vaccine patches for the simple, efficient and painless administration of vaccines through the skin, has raised US$4.0 million from Dutch investors Fare Capital, SAL Beheer, informal investors and its existing shareholders. This new funding enables Leiden based MyLife to start production of the vaccine patches for clinical studies and invest with partners in demonstration projects against COVID-19, HPV and in vaccine therapy against a variety of cancers. MyLife foresees a next series A investment round of an estimated US$17.5 million in early 2023 for the construction of a pilot plant and expansion of activities to the US and Asia.
..
MyLife is working on a reduction of vaccine doses by a factor 5 to 20 to achieve the same protection with fewer side effects

word natuurlijk een game changer en dan zou je niet meer kunnen stellen, Pharming heeft te weinig voorraad Ruconest a factor 5 to 20 maw je zou ineens 20x zoveel vrrd ruco hebben

www.lifespring.nl/view_web_version?da...

7 Posts

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	18 apr 2024 15:57
Koers	0,884
Verschil	-0,077 (-8,02%)
Hoog	0,957
Laag	0,861
Volume	28.056.638
Volume gemiddeld	6.382.260
Volume gisteren	2.891.437

Pharming nieuws meer

15:29	Pharming rondt plaatsing obligaties af	1
08:29	Pharming vervangt converteerbare lening	5
08 apr	Pharming rondt rekrutering voor klini...
14 mrt	CEO: Pharming haalt omzet uit steeds ...	2
14 mrt	Lichte plus voor AEX voorzien; zullen...
14 mrt	Pharming rekent ook voor 2024 op dubb...	2
13 mrt	Slotcall: Twijfel slaat toe bij chipp...
11 mrt	Beursblik: hogere jaaromzet Pharming ...
11 mrt	AEX gaat opnieuw rode opening tegemoe...	1
14 feb	Video-update: AEX index, Brunel en Ph...